Ecog (zubrod) Ps <= 1; Life Expectancy >=12 Wk (ECOG (Zubrod) PS <= 1; life expectancy >=12 wk)
CL Item
Granulocytes >= 1000/ul (Granulocytes >= 1000/ul)
CL Item
Histologic Dx Of Primary, Metastatic Stage Iv Or Locally Advanced, Unresectable Stage Iiib Cancer Of The Female Breast (using Ajcc Criteria, 6th Edition) Not Amenable To Local Therapy (Histologic dx of primary, metastatic Stage IV or locally advanced, unresectable Stage IIIB cancer of the female breast (using AJCC criteria, 6th edition) not amenable to local therapy)
CL Item
Inr <= 1.6, Unless On Full Dose Warfarin (INR <= 1.6, unless on full dose warfarin)
CL Item
Measurable/non-measurable Disease By Recist Criteria (Measurable/non-measurable disease by RECIST criteria)
CL Item
No Arterial Thrombotic Events, Tia, Cva, Acute Mi Or Unstable Angina Within 6 Months Of Registration (No arterial thrombotic events, TIA, CVA, acute MI or unstable angina within 6 months of registration)
CL Item
No Clinically Significant Cardiovascular Disease (No clinically significant cardiovascular disease)
CL Item
No Concurrent Active Secondary Malignancy (No concurrent active secondary malignancy)
CL Item
No History Of Abdominal Fistula Or Intraabdominal Abscess Within 6 Months Nor Gi Perforation Within 12 Months Of Registration (No history of abdominal fistula or intraabdominal abscess within 6 months nor GI perforation within 12 months of registration)
CL Item
No History Of Significant Bleeding Within 6 Months Of Registration (No history of significant bleeding within 6 months of registration)
CL Item
No Known Allergies To Aromatase Inhibitors Or Estrogen Receptor Modulators (No known allergies to aromatase inhibitors or estrogen receptor modulators)
CL Item
No Known Cns Metastases (No known CNS metastases)
CL Item
No Major Surgery Within 28 Days Of Registration (No major surgery within 28 days of registration)
CL Item
No Prior Bevacizumab Or Anti-vegf Therapy (No prior bevacizumab or anti-VEGF therapy)
CL Item
No Prior Chemotherapy For Metastatic Disease (No prior chemotherapy for metastatic disease)
CL Item
No Serious, Non-healing Wound, Ulcer Or Bone Fx (No serious, non-healing wound, ulcer or bone fx)
CL Item
Ovarian Suppression Required For Premenopausal Women (Ovarian suppression required for premenopausal women)
CL Item
Patients On Full Dose Anticoagulant Must Be On A Stable Dose Of Warfarin (Patients on full dose anticoagulant must be on a stable dose of warfarin)
Prior Adjuvant Or Neoadjuvant Chemotherapy Allowed (Prior adjuvant or neoadjuvant chemotherapy allowed)
CL Item
Prior Endocrine Therapy Not Required, But Is Permitted In Adjuvant Setting; No Prior Endocrine Therapy For Metastatic Disease Unless Initiated Within 4 Weeks Prior To Protocol Registration (Prior endocrine therapy not required, but is permitted in adjuvant setting; No prior endocrine therapy for metastatic disease unless initiated within 4 weeks prior to protocol registration)
CL Item
Transaminases (alt, Ast) <= 2.5 X Uln (Transaminases (ALT, AST) <= 2.5 x ULN)
CL Item
Tumors That Are Er And/or Pgr Positive (Tumors that are ER and/or PgR positive)
CL Item
Urinalysis <= 1+ Protein (Urinalysis <= 1+ protein)
CL Item
Women Can Be Either Pre- Or Postmenopausal (Women can be either pre- or postmenopausal)